Evidence map›Paper›PMID 35231055›Full record

ArticlePloS one2022

Searching for genetic modulators of the phenotypic heterogeneity in Brugada syndrome.

Laura Martínez-Campelo, Raquel Cruz, Alejandro Blanco-Verea, Isabel Moscoso, Eva Ramos-Luis, Ricardo Lage, María Álvarez-Barredo, María Sabater-Molina, Pablo Peñafiel-Verdú, Juan Jiménez-Jáimez and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Laura Martínez-CampeloCardiovascular Genetics, Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain.ORCID 0000-0001-7721-948X
Raquel CruzGenomic Medicine Group, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0002-6964-8898
Alejandro Blanco-VereaCardiovascular Genetics, Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain.
Isabel MoscosoCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0002-6078-4666
Eva Ramos-LuisCardiovascular Genetics, Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain.ORCID 0000-0002-2212-7403
Ricardo LageCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0002-8779-7723
María Álvarez-BarredoCardiovascular Genetics, Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain.
María Sabater-MolinaCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.ORCID 0000-0003-1352-1748
Pablo Peñafiel-VerdúCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.
Juan Jiménez-JáimezCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.
Moisés Rodríguez-MañeroCardiovascular CIBER, Carlos III Health Institute, Madrid, Spain.
María BrionCardiovascular Genetics, Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain.ORCID 0000-0001-7463-2148
Universidade de Santiago de Compostela · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Brugada syndrome, even within the same family where all affected individuals share the same mutation, phenotypic variation is prominent, with variable penetrance and expressivity, presenting different degrees of involvement. It is difficult to establish a direct correlation between genotype and phenotype to predict prognosis in complications and risk of sudden death. The factors that modulate this inter- and intra-familial phenotypic variability remain to be determined. With the intention of testing whether other genetic factors, in addition to the causal mutation in SCN5A, may have a modulating effect on the Brugada phenotype and the risk of sudden death, we have studied 8 families with a causal variant in SCN5A with at least two affected individuals, one of whom has suffered cardiac arrest or sudden death. Whole exome sequencing was performed looking for additional variants that modify the phenotype and allow us to predict a better or worse prognosis for the evolution of the disease. The results did not show any clear genetic modifier; nevertheless, highlight the possible implication of the cholesterol and fibrosis pathways, as well as the circadian rhythm, as possible modulators of Brugada syndrome phenotype.

Indexed as

Brugada SyndromeNAV1.5 Voltage-Gated Sodium ChannelPedigreePhenotypeAdultDeath, Sudden, CardiacExome SequencingFemaleHumansMaleMiddle AgedMutationNAV1.5 Voltage-Gated Sodium ChannelSCN5A protein, human

Identifiers

PMID35231055
PMCPMC8887717
OpenAlexW4214597939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.